Patents Issued in March 12, 2024
-
Patent number: 11926638Abstract: Provided are compounds having a tetradentate structure of that are useful as emitters in OLED applications.Type: GrantFiled: June 30, 2020Date of Patent: March 12, 2024Assignee: UNIVERSAL DISPLAY CORPORATIONInventors: Hsiao-Fan Chen, Jason Brooks, Chun Lin, Hai T. Le, Steven Kit Chow, Neetipalli Thrimurtulu
-
Patent number: 11926639Abstract: A process for preparing oligo ethylene glycol methyl ether borate involves feeding boric acid and oligo ethylene glycol monomethyl ether into a reactor, and reacting to obtain a raw product containing oligo ethylene glycol methyl ether borate, water, and unreacted boric acid and oligo ethylene glycol monomethyl ether. The raw product is fed to a reactive distillation device and boric acid is reacted with oligo ethylene glycmonomethyl ether for full conversion of boric acid. A distillate stream containing water is transferred from the top of the reactive distillation device to a condenser, and a condensed liquid stream is recycled to the top of the reactive distillation device. A bottom product stream containing oligo ethylene glycol methyl ether borate is withdrawn from the reactive distillation device. The bottom product stream is partially recycled to a reboiler. The resulting vapor stream is recycled to the bottom of the reactive distillation device.Type: GrantFiled: November 19, 2020Date of Patent: March 12, 2024Assignee: BASF SEInventors: Kathrin Luise Mariethres Werth, Thomas Holtmann, Rainer Papp, Mirko Haider, Joachim Wulff-Doering
-
Patent number: 11926640Abstract: The disclosure provides compounds having formula (I): and the pharmaceutically acceptable salts thereof, wherein R1, R2, R2?, and X are as defined as set forth in the specification. Compounds having formula (I) are prodrugs that release glutamine analogs, e.g., 6-diazo-5-oxo-L-norleucine (DON). The disclosure also provides compounds having formula (I) for use in treating cancer.Type: GrantFiled: March 19, 2021Date of Patent: March 12, 2024Assignees: The Johns Hopkins University, Ústav organické chemie a biochemie AV {hacek over (C)}R, v.v.i.Inventors: Barbara Slusher, Rana Rais, Lukas Tenora, Pavel Majer, Andrej Jancarik
-
Patent number: 11926641Abstract: The invention provides a compound of formula I: or a salt thereof, wherein R1-R4 have any of the values described in the specification, as well as compositions comprising a compound of formula I. The compounds are useful in immunotherapy as a potential treatment, or co-treatment, for cancer or infectious diseases.Type: GrantFiled: March 15, 2019Date of Patent: March 12, 2024Assignee: UNIVERSITY OF IOWA RESEARCH FOUNDATIONInventors: David F. Wiemer, Andrew J. Wiemer
-
Patent number: 11926642Abstract: The invention relates to compounds of formula I wherein R1, R2 and - - - - - are as defined herein, pharmaceutical compositions comprising the compounds and methods of treating COVID-19 in a patient by administering therapeutically effective amounts of the compounds and methods of inhibiting or preventing replication of SARS-CoV-2 with the compounds.Type: GrantFiled: July 1, 2021Date of Patent: March 12, 2024Assignee: Pfizer inc.Inventors: Robert Steven Kania, Padmavani Bezawada, Emma Louise Hawking, Rohit Jaini, Samir Kulkarni, Matthew Nathan O'Brien Laramy, Jonathan Richard Lillis, Suman Luthra, Dafydd Rhys Owen, Klimentina Dimitrova Pencheva, Anil Mahadeo Rane, Matthew Forrest Sammons, Bradley Paul Sullivan, Andrew John Thiel, Martyn David Ticehurst, Jamison Bryce Tuttle, Robert Louis Hoffman
-
Patent number: 11926643Abstract: This disclosure relates to GLP-1 agonists of Formula (I): including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.Type: GrantFiled: June 29, 2022Date of Patent: March 12, 2024Assignee: Gasherbrum Bio, Inc.Inventors: Qinghua Meng, Xichen Lin, Haizhen Zhang, Weiqiang Xing, Hui Lei, Andrew Jennings
-
Patent number: 11926644Abstract: Disclosed is a compound of formula (I): wherein R1, R2, R3, and are as defined herein. Also disclosed are methods for increasing mammalian cell NAD+ production and improving mitochondrial cell densities comprising administering to a cell the compound or a salt thereof.Type: GrantFiled: July 27, 2021Date of Patent: March 12, 2024Assignee: Cornell UniversityInventors: Anthony Sauve, Farheen Sultana Mohammed, Yue Yang
-
Patent number: 11926645Abstract: Compounds and methods of using said compounds, singly or in combination with additional agents, and salts, crystalline forms, pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.Type: GrantFiled: August 26, 2021Date of Patent: March 12, 2024Assignee: Gilead Sciences, Inc.Inventors: Elaine Bunyan, Byoung-Kwon Chun, Kassibla E. Dempah, Hon C. Hui, Rao V. Kalla, Richard L. Mackman
-
Patent number: 11926646Abstract: Compounds are provided according to Formula (A): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1A, R1B, n, R2A, R2B, R3, and R4 are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.Type: GrantFiled: September 15, 2021Date of Patent: March 12, 2024Assignee: Sage Therapeutics, Inc.Inventors: Francesco G. Salituro, Albert Jean Robichaud, Gabriel Martinez Botella, Andrew Griffin, Boyd L. Harrison, Daniel La
-
Patent number: 11926647Abstract: The invention encompasses components from microbial cells which are useful for antibody production, including peptides, polypeptides comprising these peptides, polynucleotides which encode these peptides or polypeptides, and antibodies directed to these peptides, polypeptides, or polynucleotides. The invention also encompasses to expression vectors and host cells for producing these peptides, polypeptides, polynucleotides, and antibodies. The invention further encompasses methods and compositions, especially vaccine compositions, for detecting, targeting, and inhibiting microbial cells, especially methanogen cells, using one or more of the disclosed peptides, polypeptides, polynucleotides, antibodies, expression vectors, and host cells.Type: GrantFiled: April 8, 2021Date of Patent: March 12, 2024Assignee: Pastoral Greenhouse Gas Research LimitedInventors: Eric Heinz Altermann, Graeme Trevor Attwood, Dong Li, William John Kelly, Zhanhao Kong, Sinead Christine Leahy
-
Patent number: 11926648Abstract: A flavivirus Envelope Dimer Epitope (EDE) and isolated neutralizing antibody or antigen binding fragment thereof directed against the EDE for use in vaccinating an individual against one or more flaviviruses wherein the EDE is a stabilized recombinant flavivirus are provided. The dimer is: covalently stabilized with at least one disulphide inter-chain bond or one sulfhydryl-reactive crosslinker between the two sE monomers, and/or by being formed as a single polypeptide chain, and/or by linking the two sE monomers through modified sugar, and/or non-covalently stabilized by substituting at least one amino acid residue in the amino acid sequence of at least one sE monomer with at least one bulky side chain amino acid, at the dimer interface or in domain 1 (D1)/domain 3 (D3) linker of each monomer. The dimer is a homodimer or heterodimer of native and/or mutant envelope polypeptides, from DENV-1, DENV-2, DENV-3, DENV-4, Zika and/or other flavivirus.Type: GrantFiled: April 27, 2021Date of Patent: March 12, 2024Assignees: INSTITUT PASTEUR, IMPERIAL COLLEGE INNOVATIONS LIMITEDInventors: Felix Rey, Giovanna Barba Spaeth, Marie-Christine Vaney, Alexander Rouvinski, Gavin Screaton, Juthathip Mongkolsapaya
-
Patent number: 11926649Abstract: The present invention provides mutant RSV F molecules, such as those that can be, or are stabilized, in a pre-fusion conformation by the introduction of one or more DT cross-links. The present invention also provides methods of making such mutant RSV F molecules, compositions comprising such mutant RSV F molecules, and methods of use of such mutant RSV F molecules, for example in vaccination methods, therapeutic methods, and antibody production methods.Type: GrantFiled: February 9, 2022Date of Patent: March 12, 2024Inventors: Christopher Marshall, Mark Yondola, Roberto Mariani, Aaron Zomback, Sonal Gidwani
-
Patent number: 11926650Abstract: The present invention relates to a method for processing fresh algae at ambient temperature by subjecting algae to an osmotic shock and treating the disrupted algae with an enzyme composition comprising cell wall degrading enzymes. This gentle process at ambient temperature allows for the isolation of algal protein which has good solubility, also in the presence of salt and good foaming, emulsifying and water binding properties. Another advantage is that this method of protein isolation allows for cascaded biorefinery, since protein isolation may be followed by a treatment of the remaining biomass with carbohydrate degrading enzymes to produce clean biogas in high yields and a mineral rich water stream in anaerobic digestion.Type: GrantFiled: December 13, 2018Date of Patent: March 12, 2024Assignee: SABIDOS B.V.Inventor: Theodorus Verleun
-
Patent number: 11926651Abstract: The present invention relates to a polypeptide construct comprising at least two fragments of an allergen from the Amb a 1 family of allergens from Ambrosia atermisiifolia or variants of said at least two fragments, wherein each of the at least two fragments consist of 20 to 50 amino acid residues and wherein at least one fragment is derived from amino acid residues 1 to 50 of the mature allergen and at least one fragment is derived from amino acid residues 240 and ending at the C-terminal end of the mature allergen.Type: GrantFiled: September 20, 2017Date of Patent: March 12, 2024Assignee: WORG PHARMACEUTICALS (ZHEJIANG) CO., LTD.Inventors: Monika Hochradl, Frank Stolz, Angela Neubauer, Rainer Henning, Elijahu Babaev
-
Patent number: 11926652Abstract: Provided herein are recombinant CTLA-4 binding proteins, which are, inter alia, useful for the treatment of cancer. The recombinant proteins provided herein are, inter alia, capable of binding CTLA-4 proteins on a tumor cell. In a first aspect, there is provided a recombinant CTLA-4 binding protein including (i) a CTLA-4 binding domain; (ii) a CTLA-4 binding domain masking peptide; and (iii) a cleavable peptide linker connecting the CTLA-4 binding domain masking peptide to the CTLA-4 binding domain. In another aspect, there is provided a dimerizing domain covalently attached to the CTLA-4 binding domain, wherein the binding protein domains are bound together.Type: GrantFiled: May 13, 2020Date of Patent: March 12, 2024Assignees: City of Hope, Thomas Jefferson University and Health System, Innovation PillarInventors: John Williams, Ulrich Rodeck, Miso Park, Kurt Jenkins
-
Patent number: 11926653Abstract: The present disclosure relates to recombinant adeno-associated vims (rAAV) delivery of a neurotrophin 3 (NT-3) polynucleotide. The disclosure provides rAAV and methods of using the rAAV for NT-3 gene therapy to improve muscle strength, stimulate muscle growth and to treat muscle wasting disorders, such as muscular dystrophy and Charcot-Marie-Tooth neuropathy.Type: GrantFiled: October 19, 2018Date of Patent: March 12, 2024Assignee: RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITALInventor: Zarife Sahenk
-
Patent number: 11926654Abstract: The present invention describes fusion proteins based on cytokines, called bi-cytokines (BC), specifically formed by the binding of an IL2 agonist mutein with a type I interferon (IFN), linked by an Fc region of a mutant human IgG1 and a connector peptide. The combination of an IL2 agonist mutein and a type I IFN in the structure of the bi-cytokines gives surprising immunoregulatory properties to these molecules and a superior therapeutic effect than that of parental cytokines, or their combination, which makes them attractive and novel molecules for the treatment of cancer. Pharmaceutical compositions comprising as an active ingredient the fusion proteins object of this patent are also described.Type: GrantFiled: March 5, 2019Date of Patent: March 12, 2024Assignee: CENTRO DE INMUNOLOGIA MOLECULARInventors: Tays Hernández García, Maura Lisett Rábade Chediak, Kalet León Monzón, Circe Mesa Pardillo, Luis Enrique Fernández Molina, Giselle Hevia Hernández
-
Patent number: 11926655Abstract: The present invention provides a novel peptide that has an amino acid sequence represented by SEQ ID NO: 18, and binds to an active protease but does not bind to a pro-protease.Type: GrantFiled: July 17, 2018Date of Patent: March 12, 2024Assignee: Daiichi Sankyo Company, LimitedInventors: Hidenori Yano, Daisuke Nishimiya, Ryuji Hashimoto, Yoichi Niitsu
-
Patent number: 11926656Abstract: Antibodies and compositions of matter useful for the detection, diagnosis and treatment of Epstein Barr Virus (EBV) infection in mammals, and methods of using those compositions of matter for the detection, diagnosis and treatment of EBV infection are described. Also described are proteins, referred to as anti-gp350 antibody probes, and anti-gp350 B-cell probes, that maintain the epitope structure of the CR2-binding region of gp350, but do not bind CR2.Type: GrantFiled: December 16, 2021Date of Patent: March 12, 2024Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Wei Bu, Masaru Kanekiyo, Michael Gordon Joyce, Jeffrey I. Cohen
-
Patent number: 11926657Abstract: Binding molecules, including bispecific antibodies that include at least two anti-influenza binding domains are disclosed, including binding molecules having a first binding domain that specifically binds influenza A virus and a second binding domain that specifically binds influenza B virus.Type: GrantFiled: November 11, 2022Date of Patent: March 12, 2024Assignee: MEDIMMUNE, LLCInventors: Nicole Kallewaard-Lelay, Qing Zhu, Godfrey Jonah Rainey, Cuihua Gao, Srinath Kasturirangan, Changshou Gao
-
Patent number: 11926658Abstract: The invention relates to multispecific antibodies, and antigen binding fragments thereof, that specifically bind to distinct Zika virus epitopes and potently neutralize infection of ZIKV. The invention also relates to nucleic acids that encode such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies and antibody fragments of the invention in prophylaxis and treatment of ZIKV infection.Type: GrantFiled: August 31, 2018Date of Patent: March 12, 2024Assignee: HUMABS BIOMED SAInventor: Davide Corti
-
Patent number: 11926659Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.Type: GrantFiled: February 22, 2021Date of Patent: March 12, 2024Assignee: Prothena Biosciences LimitedInventors: Tarlochan S. Nijjar, Robin Barbour, Philip James Dolan, III, Yue Liu, Svetlana Alexander, Mark E. Renz
-
Patent number: 11926660Abstract: The present disclosure encompasses compositions and methods for effectively treating at least one symptom or sign of Aß plaque or cerebral amyloid angiopathy (CAA) associated symptoms, or for decreasing amyloid plaque load or CAA load. The method comprises administering an effective amount of an anti-ApoE antibody to a mammalian subject, such as to a human.Type: GrantFiled: August 24, 2021Date of Patent: March 12, 2024Assignee: Washington UniversityInventors: David Holtzman, Hong Jiang, Thu Nga Bien-Ly, Mark S. Dennis, Jing Guo, Adam P. Silverman, Ryan J. Watts, Yin Zhang
-
Patent number: 11926661Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that bind to human artemin. Methods for using anti-artemin antibodies and antigen-binding fragments are also provided.Type: GrantFiled: April 19, 2022Date of Patent: March 12, 2024Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Susan D. Croll, Lynn MacDonald, Andrew J. Murphy
-
Patent number: 11926662Abstract: Provided are anti-GM-CSF antibodies or fragments thereof including humanized antibodies and fragments. Also provided are uses of the antibodies and fragments for therapeutic, diagnostic and prognostic purposes. Therapeutic uses of the antibodies and fragments, for example include the treatment of inflammatory and autoimmune diseases and disorders.Type: GrantFiled: December 2, 2020Date of Patent: March 12, 2024Assignee: I-Mab Biopharma (Hangzhou) Co., Ltd.Inventors: Zhengyi Wang, Lei Fang, Bingshi Guo, Jingwu Zang
-
Patent number: 11926663Abstract: The present invention provides means and methods for treating Interleukin 18 (IL-18)-associated diseases and disorders. In particular, the present invention discloses antibodies specific for free IL-18 and IL-18 Binding Protein (IL-18BP) for use in such treatments and for the diagnosis of the diseases and disorders.Type: GrantFiled: March 8, 2021Date of Patent: March 12, 2024Assignee: AB2 BIO SAInventors: Greg Del Val, Eduardo Schiffrin
-
Patent number: 11926664Abstract: Monocytopoiesis is a hematological process that supplies the periphery with monocytes and subsequently with macrophages and monocyte-derived dendritic cells. Typically, monocytes circulate in the bloodstream for a very short time before undergoing apoptosis, however, stimulatory signals can trigger monocyte survival by inhibiting the apoptotic pathway, and thus contribute to the maintenance of the inflammatory response. Accordingly, there is a need for methods and pharmaceutical compositions for modulating monocytopoiesis. Now, the inventors show that type I interferons signaling promote the differentiation of monocyte-derived phagocytes at the level of their progenitors. Importantly, IFN-alpha and -beta were found to efficiently generate the development of monocyte-derived antigen-presenting cells while having no impact on the precursor activity of conventional dendritic cells. Accordingly, modulators of type I interferon (e.g.Type: GrantFiled: July 24, 2018Date of Patent: March 12, 2024Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), INSTITUT PASTEUR DE LILLE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITÉ DE LILLEInventors: Lionel Poulin, Corentin Lasseaux, Mathias Chamaillard
-
Patent number: 11926665Abstract: The present disclosure provides methods of administering certain TIM-3 binding agents to patients having cancer. Dosage regimens for compositions comprising a TIM-3 binding agent are also explicitly provided.Type: GrantFiled: January 9, 2018Date of Patent: March 12, 2024Assignee: TESARO, INC.Inventors: Dmitri Bobilev, Andrew R. Ferguson, Kristen Anne McEachern, Jing Wang
-
Patent number: 11926666Abstract: The present invention relates to a bispecific antibody construct comprising a first human binding domain which binds to human CDH3 on the surface of a target cell and a second binding domain which binds to human CDS on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.Type: GrantFiled: May 3, 2021Date of Patent: March 12, 2024Assignee: AMGEN RESEARCH (MUNICH) GMBHInventors: Bertram Weiss, Anna-Lena Frisk, Ruprecht Zierz, Peter Kufer, Tobias Raum, Doris Rau, Jonas Anlahr, Ralf Lutterbüse, Lisa Nahrwold, Christoph Dahlhoff, Claudia Blümel, Patrick Hoffmann
-
Patent number: 11926667Abstract: Provided herein, in certain aspects, are antibodies that bind to CD8, as well as recombinant cells containing the vectors, and compositions comprising the antibodies. Also provided herein, in certain aspects, are antibodies that bind to CD4, as well as recombinant cells containing the vectors, and compositions comprising the antibodies. Also provided herein, in certain aspects, are multispecific antibodies that bind to CD4 and CD8, as well as recombinant cells containing the vectors, and compositions comprising the antibodies. Methods of making the antibodies are also provided.Type: GrantFiled: October 12, 2021Date of Patent: March 12, 2024Assignee: Janssen Biotech, Inc.Inventors: Rajkumar Ganesan, Sanjaya Singh, Iqbal S. Grewal, Michael Riis Hansen
-
Patent number: 11926668Abstract: The present invention provides methods for treating, reducing the severity, or inhibiting the growth of cancer (e.g., lung cancer). The methods of the present invention comprise administering a therapeutically effective amount of a programmed death 1 (PD-1) antagonist (e.g., an anti-PD-1 antibody), to a subject with lung cancer wherein the cancer tissue expresses PD-L1.Type: GrantFiled: February 28, 2022Date of Patent: March 12, 2024Assignee: Regeneron Pharmaceuticals Inc.Inventors: Petra Rietschel, Israel Lowy
-
Patent number: 11926669Abstract: The present disclosure relates to an anti-FcRn antibody or an antigen binding fragment thereof with improved stability and uses thereof. The anti-FcRn antibody or antigen binding fragment thereof binds to FcRn non-competitively with IgG and the like compared to the parent antibody, HL161AN, thereby having improved stability, such as reducing the production rate of aggregates while maintaining the biological activity of significantly reducing the amount of pathogenic autoantibodies in the blood. Therefore, it may be utilized more efficiently for the treatment of an autoimmune disease.Type: GrantFiled: June 23, 2023Date of Patent: March 12, 2024Assignees: HANALL BIOPHARMA CO., LTD., IMMUNOVANT SCIENCES GMBHInventors: William Louis Macias, Su Liang, Hyeakyung Ahn, Haeyoung Yong, Mijin Jung, Minho Yoon, Eunsun Kim, Seungkook Park, Hyeeun Shim
-
Patent number: 11926670Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-4 receptor (hIL-4R). The formulations may contain, in addition to an anti-hIL-4R antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.Type: GrantFiled: June 9, 2021Date of Patent: March 12, 2024Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Daniel B. Dix, Xiaolin Tang
-
Patent number: 11926671Abstract: The invention is in the field of antibodies useful in therapeutic and diagnostics applications targeting CD127, the alpha chain of the IL7 receptor, and provides in particular humanized monoclonal antibodies against CD127, particularly human CD127, therapeutic uses thereof, and diagnostics applications.Type: GrantFiled: June 30, 2021Date of Patent: March 12, 2024Assignee: OSE IMMUNOTHERAPEUTICSInventors: Nicolas Poirier, Caroline Mary, Bernard Vanhove, Virginie Thepenier
-
Patent number: 11926672Abstract: The present invention relates to a human agonistic CD40 multispecific antibody construct for treatment of solid tumors by engineering a molecule that specifically targets the CD40 pathway on tumor-associated APCs, without systemic CD40 activation.Type: GrantFiled: December 18, 2020Date of Patent: March 12, 2024Assignee: Amgen Inc.Inventors: Xin Yu, Jackson Egen, Fernando Garces, Shunsuke Takenaka, AeRyon Kim, Deepali Sawant
-
Patent number: 11926673Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.Type: GrantFiled: January 19, 2022Date of Patent: March 12, 2024Assignee: Bristol-Myers Squibb CompanyInventors: Aaron Yamniuk, Mary Struthers, Stanley R. Krystek, Jr., Akbar Nayeem, Ginger Rakestraw
-
Patent number: 11926674Abstract: The invention provides anti-Jagged2 antibodies and methods of using the same.Type: GrantFiled: October 30, 2020Date of Patent: March 12, 2024Assignee: Genentech, Inc.Inventors: Yvonne Chinn, Julie Q. Hang, Christian W. Siebel, Yan Wu, Daniel Lafkas
-
Patent number: 11926675Abstract: Disclosed is an antibody that specifically binds CD24, or an antigen binding portion thereof. A nucleic acid molecule encoding the antibody or antigen binding portion thereof, an expression vector and a host cell comprising the nucleic acid molecule, a method for expressing the antibody or antigen binding portion thereof, and a method for treating a disease associated with CD24 signaling using the antibody or antigen binding portion thereof are also provided.Type: GrantFiled: March 3, 2022Date of Patent: March 12, 2024Assignee: IMMUNEONCO BIOPHARMACEUTICALS (SHANGHAI) INC.Inventors: Wenzhi Tian, Song Li, Dianze Chen, Huiqin Guo
-
Patent number: 11926676Abstract: Masked chimeric antigen receptor (CAR) constructs comprising an extracellular antigen binding domain specific tyrosine-protein kinase-like 7 (PTK7), which is linked to a mask peptide that blocks binding of masked CAR from binding to PTK7. Also provided herein are genetically engineered T cells expressing a masked CAR specific to PTK7 and therapeutic uses thereof.Type: GrantFiled: May 6, 2021Date of Patent: March 12, 2024Assignee: CRISPR THERAPEUTICS AGInventors: Jason Sagert, Jui Dutta-Simmons, Jonathan Alexander Terrett
-
Patent number: 11926677Abstract: Presented herein are cancer peptide agents and uses thereof for treating cancer and/or inhibiting metastasis. Also presented herein are methods of treating cancer, or inhibiting metastasis of cancer in a subject, comprising administering a therapeutically effective amount of a composition comprising one or more cancer peptide agents to the subject. Also presented herein is a method of treating a cancer in a subject, or inhibiting metastasis of a cancer in a subject that comprises administering a therapeutically effective amount of a composition comprising one or more cancer peptide agents, and administering a chemotherapy or chemotherapeutic agent.Type: GrantFiled: October 30, 2020Date of Patent: March 12, 2024Assignee: SYMTHERA CANADA LTD.Inventor: Chai Ezerzer
-
Patent number: 11926678Abstract: Disclosed herein are composite polypeptide. According to various embodiments, the composite polypeptide includes a parent polypeptide and a metal binding motif capable of forming a complex with a metal cation. The composite polypeptide may be conjugated with a linker unit having a plurality of functional elements to form a multi-functional molecular construct. Alternatively, multiple composite polypeptides may be conjugated to a linker unit to form a molecular construct, or a polypeptide bundle. Linker units suitable for conjugating with the composite polypeptide having the metal binding motif are also disclosed.Type: GrantFiled: October 8, 2021Date of Patent: March 12, 2024Assignee: Immunwork Inc.Inventors: Tse-Wen Chang, Hsing-Mao Chu, Wei-Ting Tian, Yueh-Hsiang Yu
-
Patent number: 11926679Abstract: A modified peptide or a modified polypeptide has the amino acid sequence of Thr-Val-Asp-Ser-Cys-Leu-Thr (SEQ ID NO: 1) and adhesiveness to a norbornene-based polymer. A ratio of the total number of amino acids constituting the modified peptide or the modified polypeptide to the number of oligopeptides consisting of the amino acid sequence of SEQ ID NO: 1 contained in the modified peptide or the modified polypeptide is 7 or more and 80 or less. The number of oligopeptides consisting of the amino acid sequence of SEQ ID NO: 1 is 1.Type: GrantFiled: September 22, 2022Date of Patent: March 12, 2024Assignee: ZEON CORPORATIONInventor: Naoya Ichimura
-
Patent number: 11926680Abstract: This invention provides a method whereby Si microparticles (“Si MP”) with low cost and nitrogen-abundant chitin fibers from crustacean shells are used as raw materials to produce Si nanoparticles and nitrogen doped carbon composite via a scalable ball milling method. During the ball-milling process, Si MP are downsized, and the chitin fibers are wrapped around the particles. The milled product is then post-thermally treated to obtain Si and nitrogen doped carbon composites.Type: GrantFiled: October 1, 2020Date of Patent: March 12, 2024Assignee: University of Louisiana at LafayetteInventor: Ling Fei
-
Patent number: 11926681Abstract: A curable composition capable of forming a cured product having a high refractive index and suppressed increase in reflectance, a cured product of the curable composition, and a method for producing the cured product using the curable composition. The curable composition includes a photopolymerizable monomer, metal oxide nanoparticles, and a photopolymerization initiating agent. The photopolymerizable monomer includes a compound represented by the following formula (a1).Type: GrantFiled: June 10, 2022Date of Patent: March 12, 2024Assignee: TOKYO OHKA KOGYO CO., LTD.Inventors: Hiroki Chisaka, Shinsuke Kawatsu
-
Patent number: 11926682Abstract: The present disclosure provides a method for preparing a polymerization initiator composition, including (a) a step of mixing water and a water-soluble initiator to prepare an aqueous initiator solution having a concentration of 1 to 10%; and (b) a step of activating the aqueous initiator solution, wherein the step of activating is performed by (b-1) a step of heat treating the aqueous initiator solution for 0.5 to 4.5 hours at a temperature of 48 to 62° C.; and (b-2) a step of treating the aqueous initiator solution to achieve pH of 1 to 7, where the steps above are performed in no particular order.Type: GrantFiled: October 7, 2019Date of Patent: March 12, 2024Assignee: LG CHEM LTD.Inventors: Heung Kwon Bae, Kyung Seog Youk, Jung Rae Lee, Hyun Min Lee, Joong Chul Lim, Min Jeong Kang
-
Patent number: 11926683Abstract: The present invention provides a thermosetting material, which contains the following components (A) to (C) and which, when measured with a rotational viscometer at a constant shear rate (JIS K7117-2:1999), exhibits a viscosity at 25° C. and 10 s?1 of 5 Pa·s or more and 200 Pa·s or less and, when measured with a rotational viscometer at a constant shear rate in the same manner as above, exhibits a viscosity at 25° C. and a shear rate of 100 s?1 of 0.3 Pa·s or more and 50 Pa·s or less. (A): a (meth) acrylate compound in which a substituted or unsubstituted alicyclic hydrocarbon group having 6 or more carbon atoms is ester-bonded, and which, when measured with a rotational viscometer at a constant shear rate in the same manner as above, exhibits a viscosity of 5 to 300 mPa·s as a viscosity measured at 25° C. and 10 to 100 s?1; (B): spherical silica; and (C): a black pigment.Type: GrantFiled: June 29, 2018Date of Patent: March 12, 2024Assignee: IDEMITSU KOSAN CO., LTD.Inventors: Yutaka Obata, Haruhiko Mori
-
Patent number: 11926684Abstract: A cast film inducing a bimodal ethylene-based polymer having a high density fraction (HDF) from 3.0% to 10.0%, an I10/I2 ratio from 5.5 to 7.0, a short chain branching distribution (SCBD) less than or equal to 10° C., a density from 0.910 g/cc to 0.920 g/cc, and a melt index (I2) from 1.0 g/10 mins to 8.0 g/10 mins.Type: GrantFiled: June 13, 2019Date of Patent: March 12, 2024Assignee: Dow Global Technologies LLCInventors: Kyle E. Hart, Mehmet Demirors, Timothy W. Gambrel, Philip P. Fontaine, Vivek Kalihari, Hrishikesh R. Munj, Jon W. Hobson, Rajen M. Patel
-
Patent number: 11926685Abstract: Ethylene-based polymers of this disclosure include a melt viscosity ratio (V0.1/V100) at 190° C. of at least 10, where V0.1 is the viscosity of the ethylene-based polymer at 190° C. at a shear rate of 0.1 radians/second, and V100 is the viscosity of the ethylene-based polymer at 190° C. at a shear rate of 100 radians/second; and a molecular weight tail quantified by an MWD area metric, ATAIL, and ATAIL is less than or equal to 0.04 as determined by gel permeation chromatography using a triple detector.Type: GrantFiled: September 27, 2019Date of Patent: March 12, 2024Assignee: Dow Global Technologies LLCInventors: Teresita Kashyap, Robert D. J. Froese, Daniel J. Arriola
-
Patent number: 11926686Abstract: Shape-programmable liquid crystal elastomers. The shape-programmable liquid crystal elastomers being synthesized by filling an alignment cell with liquid crystal monomers. The liquid crystal monomers align to a surface of the alignment cell and then are polymerized with a dithiol chain transfer agent. The alignment cell is configured to impose a director orientation on a portion of the shape-programmable liquid crystal elastomer. For some embodiments, liquid crystal elastomer laminates are prepared by arranging a plurality of liquid crystal elastomers such that a director orientation of each liquid crystal elastomer of the plurality is in registered alignment with an adjacent liquid crystal elastomer of the plurality. The arrangement is secured and the plurality of liquid crystal elastomers cured.Type: GrantFiled: November 23, 2021Date of Patent: March 12, 2024Assignee: United States of America as represented by the Secretary of the Air ForceInventors: Nicholas P Godman, Timothy J White, Hilmar Koerner, Benjamin A Kowalski, Anesia D Auguste, Tyler C Guin
-
Patent number: 11926687Abstract: A grafted polypropylene resin is prepared by a grafting reaction of a polar monomer capable of absorbing microwave so as to raise its temperature in a microwave field to more than 200° C. and a solid polypropylene resin using microwave irradiation without adding an initiator. The polar grafted polypropylene resin that does not contain initiator residues and does not have a significant reduction in molecular mass compared with a resin before grafting is obtained.Type: GrantFiled: April 26, 2019Date of Patent: March 12, 2024Assignees: CHINA PETROLEUM & CHEMICAL CORPORATION, BEIJING RESEARCH INSTITUTE OF CHEMICAL INDUSTRY, CHINA PETROLEUM & CHEMICAL CORPORATIONInventors: Jinliang Qiao, Songhe Wang, Xiaohong Zhang, Guicun Qi, Zhihai Song, Chuanlun Cai, Xiang Wang, Jinmei Lai, Binghai Li, Haibin Jiang, Yue Ru, Jiangru Zhang, Jianming Gao, Hongbin Zhang, Peng Han, Wenlu Liu